Although MGMT-deficiency is particularly common in GBM, other tumor types also display MGMT deficiency [15]; by rationally combining TMZ with a DDR-inhibiting agent (TRC102), the efficacy of TMZ might be extended to malignancies beyond GBM without requiring molecular testing. Here, MGMT is linked to glioblastoma.